Investor's Stock Forecaster by Streetlight Equity

CYBN Stock Chart

FEATURED

Biotech Miracle seeking to end big pharma’s monopoly on a $28 billion industry

CYBN News

• Cybin Announces Additional Adelia Milestone Achievement
• Cybin to Announce Third Quarter Financial Results and Business Update on February 10, 2022
• Virtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021
• Cybin to Present at the Emerging Growth Conference on June 23rd
• Cybin to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th
• Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psychotherapy
• Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms
• Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder
• Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003
• Cybin Demonstrates Proof of Concept of Its Deuterated Tryptamines for the Treatment of Depression and Addiction

Investor Information

Roth Capital Partners Research Report